Articles From: Myers Industries Named One of America’s Most Trustworthy Companies 2013 by Forbes to Myriad Genetics to Announce Third Fiscal Quarter 2013 Results on Tuesday, May 7, 2013


2013/3/22
For the second year in a row, Myers Industries, Inc. (NYSE: MYE) has been named one of America’s 100 Most Trustworthy Companies in an annual survey commissioned by Forbes .
Sign-up for Myers Industries Named One of America’s Most Trustworthy Companies 2013 by Forbes investment picks
2013/2/13
Myers Industries, Inc. (NYSE: MYE) today announced results for the full year and fourth quarter ended December 31, 2012.
Sign-up for Myers Industries Reports 2012 Full Year and Fourth Quarter Results investment picks
2013/4/24
Myers Industries, Inc. (NYSE: MYE) today announced results for the first quarter ended March 31, 2013.
Sign-up for Myers Industries Reports 2013 First Quarter Results investment picks
2013/4/22
Pledge Supports Campaign's Goal to Raise Additional $90 Million for Scholarships over Next Two Years PITTSBURGH , April 22, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has contributed $1 million to The Pittsburgh Promise Scholarship Fund, a scholarship program for Pittsburgh Public School students that advocates for improving the quality of education and increasing the preparedness and diversity of the region's workforce.
Sign-up for Mylan Announces $1 Million Gift to The Pittsburgh Promise Scholarship Fund investment picks
2013/3/13
PITTSBURGH , March 13, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with Shionogi Inc. and Andrx that will resolve patent litigation related to Metformin Hydrochloride Extended-release Tablets USP, 500 mg and 1000 mg.
Sign-up for Mylan Announces Fortamet® Settlement Agreement investment picks
2013/2/11
PITTSBURGH , Feb.
Sign-up for Mylan Appoints Melina Higgins and Rajiv Malik to Board of Directors investment picks
2013/2/13
PITTSBURGH , Feb.
Sign-up for Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products investment picks
2013/3/4
PITTSBURGH , March 4, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Annual Report on Form 10-K, containing audited consolidated financial statements for the year ended Dec.
Sign-up for Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2012 investment picks
2013/4/3
PITTSBURGH , April 3, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acyclovir Ointment USP, 5%. This product is the first generic version of Valeant International's Zovirax ® Ointment, which is indicated in the management of initial genital herpes and in limited non-life-threatening mucocutaneous herpes simplex virus infections in immunocompromised patients.
Sign-up for Mylan Launches First Generic Version of Zovirax® Ointment investment picks
2013/2/25
PITTSBURGH , Feb.
Sign-up for Mylan Launches Generic Antara® Capsules investment picks
2013/3/18
PITTSBURGH , March 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate). This product is the generic version of Sunovion's Xopenex ® Inhalation Solution, which is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.
Sign-up for Mylan Launches Generic Version of Xopenex® Inhalation Solution investment picks
2013/2/23
Builds on Existing South African Commercial Business JOHANNESBURG and PITTSBURGH , Feb.
Sign-up for Mylan Launches Innovative Portfolio of Antiretroviral Products for Treatment of HIV/AIDS in South Africa investment picks
2013/5/2
Reaffirms 2013 Adjusted Diluted EPS Guidance Range of $2.75 - $2.95 PITTSBURGH , May 2, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three months ended March 31, 2013.
Sign-up for Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62 investment picks
2013/2/27
Announces 2013 adjusted diluted EPS guidance range of $2.75 - $2.95 PITTSBURGH , Feb.
Sign-up for Mylan Reports a 23% Increase in Fourth Quarter 2012 Adjusted Diluted EPS to $0.65 investment picks
2013/4/9
PITTSBURGH , April 9, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast Thursday, May 2, 2013 , at 4:30 p.m. ET , to review the company's financial results for the first quarter, which ended March 31, 2013 .
Sign-up for Mylan Schedules First Quarter 2013 Financial Results Conference Call and Live Webcast investment picks
2013/2/13
PITTSBURGH , Feb.
Sign-up for Mylan Schedules Fourth Quarter and Year End 2012 Financial Results Conference Call and Live Webcast investment picks
2013/4/25
Marketer of EpiPen® Auto-Injector, the No.
Sign-up for Mylan Specialty L.P. Announces 25th Anniversary Celebration of EpiPen® (epinephrine) Auto-Injector investment picks
2013/2/27
Acquisition expected to be immediately accretive to adjusted diluted EPS upon closing PITTSBURGH , Feb.
Sign-up for Mylan to Acquire Agila to Create Leading Global Injectables Platform investment picks
2013/3/4
MYPLASH, the reloadable and responsible prepaid MasterCard® for teens and young adults, is pleased to announce an exciting new partnership with SKECHERS – America’s top family footwear brand – to promote financial literacy and support shoe donations to children in need via their charitable BOBS from SKECHERS program.
Sign-up for MYPLASH Gives Back With BOBS From SKECHERS Partnership investment picks
2013/5/1
ROLLING MEADOWS, Ill., May 1, 2013 (GLOBE NEWSWIRE) -- MYR Group Inc. ("MYR") (Nasdaq:MYRG) , a leading specialty contractor serving the electrical infrastructure market in the United States, announced it will release first-quarter 2013 results on Wednesday, May 8, 2013, after the close of trading.
Sign-up for MYR Group Inc. Announces 2013 First-Quarter Conference Call Schedule investment picks
2013/5/8
ROLLING MEADOWS, Ill., May 8, 2013 (GLOBE NEWSWIRE) -- MYR Group Inc. ("MYR") (Nasdaq:MYRG) , a leading specialty contractor serving the electrical infrastructure market in the United States, today announced its first-quarter 2013 financial results.
Sign-up for MYR Group Inc. Announces First-Quarter 2013 Results investment picks
2013/2/27
ROLLING MEADOWS, Ill., Feb.
Sign-up for MYR Group Inc. Announces Fourth-Quarter and Full-Year 2012 Earnings Release and Conference Call Schedule investment picks
2013/3/6
ROLLING MEADOWS, Ill., March 6, 2013 (GLOBE NEWSWIRE) -- MYR Group Inc. ("MYR") (Nasdaq:MYRG) , a leading specialty contractor serving the electrical infrastructure market in the United States, today announced its fourth-quarter and full-year 2012 financial results.
Sign-up for MYR Group Inc. Announces Fourth-Quarter and Full-Year 2012 Results investment picks
2013/5/6
ROLLING MEADOWS, Ill., May 6, 2013 (GLOBE NEWSWIRE) -- MYR Group Inc. ("MYR") (Nasdaq:MYRG) , a leading specialty contractor serving the electrical infrastructure market in the United States, announced today that MYR Group Chief Operating Officer (COO), Richard S.
Sign-up for MYR Group Inc. Announces Promotion of COO Rick Swartz to President of MYR Subsidiaries investment picks
2013/4/17
SALT LAKE CITY and LEXINGTON, Mass., April 17, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) and RainDance Technologies, Inc. today announced that they have entered into a commercial agreement whereby Myriad will adopt RainDance's ThunderStorm™ Target Enrichment System for Myriad's next-generation sequencing based Hereditary Cancer Panel (HCP) test.
Sign-up for Myriad Adopts RainDance's Thunderstorm Platform for Next-Generation Sequencing Based Hereditary Cancer Panel investment picks
2013/3/26
SALT LAKE CITY, March 26, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement with PharmaMar, a leader in the development of marine-derived drugs.
Sign-up for Myriad and PharmaMar Announce First Commercial Partnership With Myriad's New HRD Test investment picks
2013/5/2
SALT LAKE CITY, May 2, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its Analyst and Investor Day for research analysts and institutional investors will take place on Thursday, May 9, 2013 at 9:00 a.m. EST in New York City.
Sign-up for Myriad Genetics Announces 2013 Analyst and Investor Day investment picks
2013/2/5
SALT LAKE CITY, Feb.
Sign-up for Myriad Genetics Reports Second Quarter Fiscal Year 2013 Results investment picks
2013/5/7
SALT LAKE CITY, May 7, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its third fiscal quarter and nine months ended March 31, 2013.
Sign-up for Myriad Genetics Reports Third Quarter Fiscal Year 2013 Results investment picks
2013/4/18
SALT LAKE CITY, April 18, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the third fiscal quarter 2013 following the close of market on Tuesday, May 7, 2013.
Sign-up for Myriad Genetics to Announce Third Fiscal Quarter 2013 Results on Tuesday, May 7, 2013 investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Myers Industries Named One of America’s Most Trustworthy Companies 2013 by Forbes to Myriad Genetics to Announce Third Fiscal Quarter 2013 Results on Tuesday, May 7, 2013
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity